Prospective study of Type 2 diabetes mellitus, anti-diabetic drugs and risk of prostate cancer

Fall, 2013, Diabetes mellitus and prostate cancer risk: a nationwide case-control study within PCBaSe Sweden, Cancer Epidemiol Biomarkers Prev, 22, 1102, 10.1158/1055-9965.EPI-12-1046

Bonovas, 2004, Diabetes mellitus and risk of prostate cancer: a meta-analysis, Diabetologia, 47, 1071, 10.1007/s00125-004-1415-6

Kasper, 2006, A meta-analysis of diabetes mellitus and the risk of prostate cancer, Cancer Epidemiol Biomarkers Prev, 15, 2056, 10.1158/1055-9965.EPI-06-0410

Atchison, 2011, Risk of cancer in a large cohort of U.S. veterans with diabetes, Int J Cancer, 128, 635, 10.1002/ijc.25362

Walker, 2013, Type 2 diabetes, socioeconomic status and risk of cancer in Scotland 2001-2007, Diabetologia, 56, 1712, 10.1007/s00125-013-2937-6

Tsilidis, 2015, Type 2 diabetes and cancer: umbrella review of meta-analyses of observational studies, BMJ, 350, g7607, 10.1136/bmj.g7607

Murtola, 2008, Antidiabetic medication and prostate cancer risk: a population-based case-control study, Am J Epidemiol, 168, 925, 10.1093/aje/kwn190

Preston, 2014, Metformin use and prostate cancer risk, Eur Urol, 66, 1012, 10.1016/j.eururo.2014.04.027

Tseng, 2014, Metformin significantly reduces incident prostate cancer risk in Taiwanese men with type 2 diabetes mellitus, Eur J Cancer, 50, 2831, 10.1016/j.ejca.2014.08.007

Wright, 2009, Metformin use and prostate cancer in Caucasian men: results from a population-based case-control study, Cancer Cause Control, 20, 1617, 10.1007/s10552-009-9407-y

Margel, 2013, Association between metformin use and risk of prostate cancer and its grade, J Natl Cancer Inst, 105, 1123, 10.1093/jnci/djt170

Chen, 2013, Insulin therapy and risk of prostate cancer: a systematic review and meta-analysis of observational studies, PLoS One, 8

Karlstad, 2013, Use of insulin and insulin analogs and risk of cancer-systematic review and meta-analysis of observational studies, Curr Drug Safety, 8, 333, 10.2174/15680266113136660067

Tsilidis, 2014, Metformin does not affect cancer risk: a cohort study in the UK clinical practice research datalink analyzed like an intention-to-treat trial, Diabetes Care, 37, 2522, 10.2337/dc14-0584

Harding, 2015, Cancer risk among people with type 1 and type 2 diabetes: disentangling true associations, detection bias, and reverse causation (vol 38, pg 264, 2015), Diabetes Care, 38, 734, 10.2337/dc14-1996

Johnson, 2011, Time-varying incidence of cancer after the onset of type 2 diabetes: evidence of potential detection bias, Diabetologia, 54, 2263, 10.1007/s00125-011-2242-1

Johnson, 2012, Diabetes and cancer (1): evaluating the temporal relationship between type 2 diabetes and cancer incidence, Diabetologia, 55, 1607, 10.1007/s00125-012-2525-1

Suissa, 2012, Metformin and the risk of cancer: time-related biases in observational studies, Diabetes Care, 35, 2665, 10.2337/dc12-0788

Hemelrijck, 2013, Cohort profile: The National Prostate Cancer Register of Sweden and Prostate Cancer data Base Sweden 2.0, Int J Epidemiol, 42, 956, 10.1093/ije/dys068

Charlson, 1987, A new method of classifying prognostic co-morbidity in longitudinal-studies-development and validation, J Chron Dis, 40, 373, 10.1016/0021-9681(87)90171-8

Berglund, 2011, Comorbidity, treatment and mortality: a population based cohort study of prostate cancer in PCBaSe Sweden, J Urol, 185, 833, 10.1016/j.juro.2010.10.061

Statistics Sweden Longitudinal integration database for health insurance and labour market studies (LISA by Swedish acronym) http://www.scb.se/lisa-en

The Swedish National Diabetes Register (NDR) Annual report 2014 https://www.ndr.nu/pdfs/Arsrapport_NDR_2014.pdf

Gudbjornsdottir, 2003, The National Diabetes Register in Sweden: an implementation of the St. Vincent Declaration for Quality Improvement in Diabetes Care, Diabetes Care, 26, 1270, 10.2337/diacare.26.4.1270

White, 2011, Multiple imputation using chained equations: issues and guidance for practice, Stat Med, 30, 377, 10.1002/sim.4067

National Comprehensive Cancer Network NCCN Guidelines 2012 http://www.nccn.org/professionals/physician_gls/pdf/prostate.pdf

Jian, 2014, Diabetes mellitus and the risk of prostate cancer: an update and cumulative meta-analysis, Endocr Res, 1

Waters, 2009, Association of diabetes with prostate cancer risk in the multiethnic cohort, Am J Epidemiol, 169, 937, 10.1093/aje/kwp003

Kasper, 2009, Diabetes mellitus and risk of prostate cancer in the health professionals follow-up study, Int J Cancer, 124, 1398, 10.1002/ijc.24044

Leitzmann, 2008, Diabetes mellitus and prostate cancer risk in the prostate, lung, colorectal, and ovarian cancer screening trial, Cancer Causes Control, 19, 1267, 10.1007/s10552-008-9198-6

Carstensen, 2012, Cancer occurrence in Danish diabetic patients: duration and insulin effects, Diabetologia, 55, 948, 10.1007/s00125-011-2381-4

Rodriguez, 2005, Diabetes and risk of prostate cancer in a prospective cohort of US men, Am J Epidemiol, 161, 147, 10.1093/aje/kwh334

Tsilidis, 2015, Diabetes mellitus and risk of prostate cancer in the European prospective investigation into cancer and nutrition, Cancer, 136

Xu, 2013, Diabetes mellitus and prostate cancer risk of different grade or stage: a systematic review and meta-analysis. Diabetes, Res Clin Pract, 99, 241, 10.1016/j.diabres.2012.12.003

Calton, 2007, History of diabetes mellitus and subsequent prostate cancer risk in the NIH-AARP Diet and Health Study, Cancer Cause Control, 18, 493, 10.1007/s10552-007-0126-y

Sarma, 2009, Diabetes and benign prostatic hyperplasia/lower urinary tract symptoms-what do we know?, J Urol, 182, S32, 10.1016/j.juro.2009.07.088

Parsons, 2010, Benign prostatic hyperplasia and male lower urinary tract symptoms: epidemiology and risk factors, Curr Bladder Dysfunct Rep, 5, 212, 10.1007/s11884-010-0067-2

Barry, 1992, The American Urological Association symptom index for benign prostatic hyperplasia. The Measurement Committee of the American Urological Association, J Urol, 148, 1549, 10.1016/S0022-5347(17)36966-5

Rohrmann, 2005, Association between markers of the metabolic syndrome and lower urinary tract symptoms in the Third National Health and Nutrition Examination Survey (NHANES III), Int J Obes (Lond), 29, 310, 10.1038/sj.ijo.0802881

Feng, 2015, Metformin use and risk of prostate cancer: results from the REDUCE study, Cancer Prev Res (Phila), 8, 1055, 10.1158/1940-6207.CAPR-15-0141

Azoulay, 2011, Metformin and the incidence of prostate cancer in patients with type 2 diabetes, Cancer Epidemiol Biomarkers Prev, 20, 337, 10.1158/1055-9965.EPI-10-0940

Noto, 2012, Cancer risk in diabetic patients treated with metformin: a systematic review and meta-analysis, PLoS One, 7, e33411, 10.1371/journal.pone.0033411

Franciosi, 2013, Metformin therapy and risk of cancer in patients with type 2 diabetes: systematic review, PLoS One, 8, e71583, 10.1371/journal.pone.0071583

Soranna, 2012, Cancer risk associated with use of metformin and sulfonylurea in type 2 diabetes: a meta-analysis, Oncologist, 17, 813, 10.1634/theoncologist.2011-0462

Rastmanesh, 2014, Type 2 diabetes: a protective factor for prostate cancer? An overview of proposed mechanisms, Clin Genitourin Cancer, 10.1016/j.clgc.2014.01.001

Pierce, 2010, Genetic susceptibility to type 2 diabetes is associated with reduced prostate cancer risk, Hum Hered, 69, 193, 10.1159/000289594

Pierce, 2012, Why are diabetics at reduced risk for prostate cancer? A review of the epidemiologic evidence, Urol Oncol, 30, 735, 10.1016/j.urolonc.2012.07.008

Carstensen, 2014, The epidemiology of diabetes and cancer, Curr Diab Rep, 14, 535, 10.1007/s11892-014-0535-8

Ekstrom, 2012, Glucose-lowering treatment and clinical results in 163 121 patients with type 2 diabetes: an observational study from the Swedish national diabetes register, Diabetes Obes Metab, 14, 717, 10.1111/j.1463-1326.2012.01591.x

Stocks, 2007, Insulin resistance is inversely related to prostate cancer: a prospective study in Northern Sweden, Int J Cancer, 120, 2678, 10.1002/ijc.22587